XBIO
Xenetic Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.77
+12.60%Sep 16, 2026, 11:02 UTC
Xenetic Biosciences signed a Share Exchange Agreement to acquire all issued share capital of Santersus AG, with Santersus shareholders expected to hold about 85% of the combined company, which will be renamed Santersus Bio, Inc.
Source:Aug 7, 2026, 12:35 UTC
Xenetic Biosciences reported financial results for the quarter ended June 30, 2026, and provided a corporate update on its DNase platform development strategy.
Source:Jun 4, 2026, 12:40 UTC
PeriNess Ltd., collaboration partner of Xenetic Biosciences, received approval from the Israeli Ministry of Health to conduct an investigator-initiated study of DNase I in combination with anti-CD19 CAR T cells in large B-cell lymphoma.